Peng Wang Appointed WuXi PharmaTech VP of Discovery Biology
WuXi PharmaTech (Shanghai, China) has appointed Peng Wang, PhD as vice president of discovery biology.
WuXi PharmaTech (Shanghai, China) has appointed Peng Wang, PhD as vice president of discovery biology. Prior to joining WuXi PharmaTech, Wang was a research fellow at the Schering-Plough Research Institute, where he worked for 18 years. He has extensive experience in discovery biology, including target validation research, assay development, screening, in vitro, and in vivo biological and pharmacological studies, and biomarker research. In his new role, Wang will oversee the WuXi PharmaTech’s portfolio of discovery biology service offerings.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
